CD4 and melanoma: To test this hypothesis, we utilized a preclinical mouse model whereby the adoptive transfer of naive CD4+ T cells specific for Tyrp1, a melanoma differentiation antigen, results in conversion to cytotoxic T cells in vivo and inhibition of tumor growth in lymphopenic murine hosts by direct tumor cell killing [33].